Inhibitors of CYP 17

Abstract

The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R 53 , R 54 , p, q, and n are as defined herein. The compounds of the present invention have been found to be useful as 17α-hydroxylase/C 17,20 -lyase inhibitors.

What is claimed is: 
     
       1. A compound of Formula (Ib) 
       
         
           
           
               
               
           
         
       
       wherein
 R 50 , R 51  and R 52  are each independently H, halo, -OH, -CN, (C 1 -C 4 )alkyl, halo-substituted(C 1 -C 4 )alkyl, hydroxy-substituted (C 1 -C 4 )alkyl, -(CH 2 ) r  -O(C 1 -C 4 )alkyl, -(CH 2 ) r —CH(O(C 1 -C 4 )alkyl) 2 , -NH 2 , -NH(C 1 -C 4 )alkyl, -N((C 1 -C 4 )alkyl) 2 , -NHC(O)-(C 1 -C 4 )alkyl, —C(O)NH 2 , -C(O)-NH(C 1 -C 4 )alkyl, -C(O)-N((C 1 -C 4 )alkyl) 2 , or -C(O)-O(C 1 -C 4 )alkyl; 
 
       wherein
 n is 1; 
 R 53  is 
 (i) phenyl optionally substituted with 1 to 3 substituents selected from halo, -CN, -OH, (C 1 -C 6 )alkyl, halo-substituted (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, -NH 2 , -NH(C 1 -C 4 )alkyl, -N((C 1 -C 4 )alkyl) 2 , -NHC(O)-(C 1 -C 4 )alkyl, -C(O)NH 2 , -C(O)-NH(C 1 -C 4 )alkyl, -C(O)-N((C 1 -C 4 )alkyl) 2 , or a 5- to 6-membered heterocycle, 
 (ii) biphenyl optionally substituted with 1 to 3 substituents selected from (C 1 -C 4 )alkyl or halo, 
 (iii) phenyl fused to an additional phenyl, a 5- to 6-membered heteroaryl, a 5- to 6-membered partially or fully saturated cycloalkyl, or a 5- to 6-membered partially or fully saturated heterocycle, where said fused phenyl is optionally substituted with 1 to 4 substituents each independently selected from halo, -CN, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy-substituted (C 1 -C 4 )alkyl, halo-substituted (C 1 -C 4 )alkyl, cyclopropyl, oxo, -NH 2 , -NH(C 1 -C 4 )alkyl, -N((C 1 -C 4 )alkyl) 2 , -NHC(O)-(C 1 -C 4 )alkyl, or ═N-OH, 
 (iv) 5- to 6-membered heteroaryl optionally substituted with 1 to 3 substituents selected from halo, -CN, -OH, (C 1 -C 6 )akyl, halo-substituted (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, -NH 2 , -NH(C 1 -C 4 )alkyl, -N((C 1 -C 4 )alkyl) 2 , -NHC(O)-(C 1 -C 4 )alkyl, -C(O)NH 2 , -C(O)-NH(C 1 -C 4 )alkyl, -C(O)-N((C 1 -C 4 )alkyl) 2 , or a 5- to 6-membered Heterocycle, 
 (v) 5- to 6-membered heteroaryl fused to another 5- to 6-membered heteroaryl, phenyl, 5- to 6-membered partially or fully saturated cycloalkyl, or a 5- to 6-membered partially or fully saturated heterocycle, where said fused heteroaryl is optionally substituted with 1 to 4 substituents each independently selected from halo, -CN, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy-substituted (C 1 -C 4 )alkyl, halo-substituted (C 1 -C 4 )alkyl, cyclopropyl,  oxo, -NH 2 , -NH(C 1 -C 4 )alkyl, -N((C 1 -C 4 )alkyl) 2 , -NHC(O)-(C 1 -C 4 )alkyl, or ═N-OH; 
 R 54  is (C 1 -C 4 )alkyl, halo-substituted (C 1 -C 4 )alkyl, or -CH 2 OH, or two R 54  taken together with the carbon atom(s) to which they are attached form a 3- to 6-membered fully or partially saturated carbocyclic; 
 p is 0, 1, 2, or 3; 
 with the proviso that when R 50 , R 51 , and R 52  are H and R 53  is phenyl, R 53  is not unsubstituted or substituted with halogen or CF 3 , 
 
       or a pharmaceutically acceptable salt thereof. 
     
     
       2. A compound of Formula (Ib) 
       
         
           
           
               
               
           
         
       
       wherein:
 n is 1; 
 R 53  is 
 (i) phenyl optionally substituted with 1 to 3 substituents selected from halo, -CN, -OH, (C 1 -C 6 )alkyl, halo-substituted (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, -NH 2 , -NH(C 1 -C 4 )alkyl, -N((C 1 -C 4 )alkyl) 2 , -NHC(O)-(C 1 -C 4 )alkyl, -C(O)NH 2 , -C(O)-NH(C 1 -C 4 )alkyl, -C(O)-N((C 1 -C 4 )alkyl) 2 , or a 5- to 6-membered heterocycle, 
 (ii) biphenyl optionally substituted with 1 to 3 substituents selected from (C 1 -C 4 )alkyl or halo, 
 (iii) phenyl fused to an additional phenyl, a 5- to 6-membered heteroaryl, a 5- to 6-membered partially or fully saturated cycloalkyl, or a 5- to 6-membered partially or fully saturated heterocycle, where said fused phenyl is optionally substituted with 1 to 4 substituents each independently selected from halo, -CN, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy-substituted (C 1 -C 4 )alkyl, halo-substituted (C 1 -C 4 )alkyl, cyclopropyl, oxo, -NH 2 , -NH(C 1 -C 4 )alkyl, -N((C 1 -C 4 )alkyl) 2 , -NHC(O)-(C 1 -C 4 )alkyl, or ═N-OH, 
 (iv) 5- to 6-membered heteroaryl optionally substituted with 1 to 3 substituents selected from halo, -CN, -OH, (C 1 -C 6 )alkyl, halo-substituted (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, -NH 2 , -NH(C 1 -C 4 )alkyl, -N((C 1 -C 4 )alkyl) 2 , -NHC(O)-(C 1 -C 4 )alkyl, -C(O)NH 2 , -C(O)-NH(C 1 -C 4 )alkyl, -C(O)-N((C 1 -C 4 )alkyl) 2 , or a 5- to 6-membered heterocycle, 
 (v) 5- to 6-membered heteroaryl fused to another 5- to 6-membered heteroaryl, phenyl, 5- to 6-membered partially or fully saturated cycloalkyl, or a 5- to 6-membered partially or fully saturated heterocycle, where said fused heteroaryl is optionally substituted with 1 to 4 substituents each independently selected from halo, -CN, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy-substituted (C 1 -C 4 )alkyl, halo-substituted (C 1 -C 4 )alkyl, cyclopropyl, oxo, -NH 2 , -NH(C 1 -C 4 )alkyl, -N((C 1 -C 4 )alkyl) 2 , -NHC(O)-(C 1 -C 4 )alkyl, or ═N-OH; 
 (i) a phenyl optionally substituted with 1 to 2 substituents each independently selected from fluoro, chloro, methyl, methoxy, trifluoromethyl, difluoromethyl, or cyano; 
 (ii) a biphenyl; 
 (iii) a fused phenyl selected from naphthalen-2-yl, quinolin-6-yl, 3,4-dihydro-2-oxo-quinolin-6-yl, benzo[b]thiophen-5-yl, benzo[d]isoxazol-5-yl, 1H-indazol-6-yl, 1H-indazol-5-yl, benzothiazol-6-yl, 1,2-dihydro-3-oxo-indazol-6-yl, indan-5-yl, 1H-benzotriazol-5-yl, benzofuran-5-yl, 2,3-dihydro-benzo[1,4]dioxin-6-yl, 2,3-dihydro-benzofuran-5-yl, or benzo[1,3]dioxol-5-yl where said fused phenyl is optionally substituted with 1 to 2 substituents each independently selected from chloro, fluoro, methyl, ethyl, difluoromethyl, trifluoromethyl, cyclopropyl, cyano, or amino; 
 (iv) a 5- to 6-membered heteroaryl selected from isothiazol-4-yl, thiophen-2-yl, thiophen-3-yl, or pyridin-4-yl, where said isothiazol-4-yl, said thiophen-2-yl, said thiophen-3-yl, and said pyridin-4-yl are optionally substituted with fluoro, chloro, methyl, trifluoromethyl, difluoromethyl, or methoxy; or 
 (v) a fused heteroaryl selected from thieno[3,2-c]pyridin-2-yl, thieno[3,2-c]pyridin-3-yl, thieno[3,2-c]pyridin-2-yl, imidazo[1,2-a]pyridin-7-yl, or benzo[b]thiophen-2-yl, where said fused heteroaryl is optionally substituted with 1 to 2 substituents each independently selected from fluoro, chloro, methyl, difluoromethyl, trifluoromethyl, cyclopropyl, or amino;  
 R 54  is (C 1 -C 4 )alkyl, halo-substituted (C 1 -C 4 )alkyl, or -CH 2 OH, or two R 54  taken together with the carbon atom(s) to which they are attached form a 3- to 6-membered fully or partially saturated carbocyclic ring; 
 p is 0, 1, 2, or 3; 
 R 50 , R 51  and R 52  are each independently H, halo, -OH, -CN, (C 1 -C 4 )alkyl, halo-substituted (C 1 -C 4 )alkyl, hydroxy-substituted (C 1 -C 4 )alkyl, -(CH 2 ) r -O(C 1 -C 4 )alkyl, -(CH 2 ) r —CH(O(C 1 -C 4 )alkyl) 2 , -NH 2 , -NH(C 1 -C 4 )alkyl, -N((C 1 -C 4 )alkyl) 2 , -NHC(O)-(C 1 -C 4 )alkyl, -C(O)NH 2 , -C(O)-NH(C 1 -C 4 )alkyl, -C(O)-N((C 1 -C 4 )alkyl) 2 , or -C(O)-O(C 1 -C 4 )alkyl; 
 r is 0, 1 or 2; 
 with the proviso that when R 50 , R 51 , and R 52  are H and R 53  is phenyl, R 53  is not unsubstituted or substituted with halogen or CF 3 ; 
 or a pharmaceutically acceptable salt thereof. 
 
     
     
       3. The compound of  claim 2  wherein R 54  is -CH 3  or CF 3 ; or a pharmaceutically acceptable salt thereof. 
     
     
       4. The compound of  claim 2  wherein R 50  is H or methyl; R 51  is H, halo, methyl, trifluoromethyl, methoxy, or -C(O)OCH 3 ; and R 52  is halo, -CN, methyl, ethyl, methoxy, hydroxymethyl, 1-hydroxyethyl, 2-hydroxypropan-2-yl, difluoromethyl, trifluoromethyl, dimethoxymethyl, -NH 2 , or -NHC(O)CH 3 ; or a pharmaceutically acceptable salt thereof. 
     
     
       5. The compound of  claim 2  wherein R 53  is
 (i) a phenyl optionally substituted with 1 or 2 substituents each independently selected form fluoro, chloro, cyano, methyl, difluoromethyl, trifluoromethyl, methoxy, or —C(O)NHCH 3 ; 
 (ii) a biphenyl optionally substituted with fluoro; 
 (iii) a fused phenyl selected from naphthalen-2-yl, naphthalen-1-yl, 1H-indol-5-yl, 1H-indol-6-yl, benzothiazol-5-yl, benzothiazol-6-yl, 1,2,3,4-tetrahydro-quinolin-6-yl, benzo[b]thiophen-5-yl, quinolin-6-yl, quinolin-7-yl, indan-5-yl, 1,2-dihydroquinolin-6-yl, 1H-indazol-5-yl, 1H-indazol-6-yl, benzofuran-5-yl, 2,3-dihydrobenzo[1,4]dioxin-6-yl, 2,3-dihydro-benzofuran-5-yl, benzo[1,3]dioxol-5-yl, 1,2,3,4-tetrahydro-quinolin-7-yl, quinoxalin-6-yl, benzooxazol-5-yl, benzo[d]isoxazol-5-yl, benzo[d]isoxazol-6-yl, 1H-benzoimidazol-5-yl, 2,3-dihydro-1H-indazol-5-yl, 2,3-dihydro-1H-indazol-6-yl, indolin-5-yl, or 1 H-benzotriazol-5-yl, where said fused phenyl is optionally substituted with 1 to 3 substituents each independently selected from fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, oxo, -NH 2 , ═N-OH or cyclopropyl; 
 (iv) a 5- to 6-membered heteroaryl selected from thiophen-2-yl, thiophen-3-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-5-yl, 1H-pyrazol-4-yl, thiazol-2-yl, or isothiazol-4-yl, where said 5- to 6-membered heteroaryl is optionally substituted with 1 to 3 substituents each independently selected from fluoro, chloro, methyl, ethyl, isopropyl, hydroxy, difluoromethyl, trifluoromethyl, methoxy, -NH 2 , -NHC(O)CH 3 , -C(O)NHCH 3 , or pyrrolidin-1-yl; or 
 (v) a fused heteroaryl selected from benzo[b]thiophen-2-yl, benzo[b]thiophen-3-yl, quinolin-2-yl, quinolin-3-yl, benzooxazol-2-yl, benzothiazol-2-yl, 4,5,6,7-tetrahydro-thieno[2,3-c]pyridin-2-yl, imidazo[1,2-a]pyridin-3-yl, imidazo[1,2-a]pyridin-6-yl, imidazo[1,2-a]pyridin-7-yl, 3H-imidazo[4,5-b]pyridin-6-yl, thieno[3,2-c]pyridin-2-yl, thieno[3,2-c]pyridin-3-yl, or 1H-indol-3-yl, where said fused heteroaryl is optionally substituted with 1 to 4 substituents each independently selected from fluoro, chloro, cyano, methyl, or methoxy; 
 or a pharmaceutically acceptable salt thereof. 
 
     
     
       6. The compound of  claim 2  wherein R 53  is
 (i) a phenyl optionally substituted with 1 to 2 substituents each independently selected from fluoro, chloro, methyl, methoxy, trifluoromethyl, difluoromethyl, or cyano; 
 (ii) a biphenyl; 
 (iii) a fused phenyl selected from naphthalen-2-yl, quinolin-6-yl, 3,4-dihydro-2-oxo-quinolin-6-yl, benzo[b]thiophen-5-yl, benzo[d]isoxazol-5-yl, 1H-indazol-6-yl, 1H-indazol-5-yl, benzothiazol-6-yl, 1,2-dihydro-3-oxo-indazol-6-yl, indan-5-yl, 1H-benzotriazol-5-yl, benzofuran-5-yl, 2,3-dihydro-benzo[1,4]dioxin-6-yl, 2,3-dihydro-benzofuran-5-yl, or benzo[1,3]dioxol-5-yl where said fused phenyl is optionally substituted with 1 to 2 substituents each independently selected from chloro, fluoro, methyl, ethyl, difluoromethyl, trifluoromethyl, cyclopropyl, cyano, or amino; 
 (iv) a 5- to 6-membered heteroaryl selected from isothiazol-4-yl, thiophen-2-yl, thiophen-3-yl, or pyridin-4-yl, where said isothiazol-4-yl, said thiophen-2-yl, said thiophen-3-yl, and said pyridin-4-yl are optionally substituted with fluoro, chloro, methyl, trifluoromethyl, difluoromethyl, or methoxy; or 
 (v) a fused heteroaryl selected from thieno[3,2-c]pyridin-2-yl, thieno[3,2-c]pyridin-3-yl, thieno[3,2-c]pyridin-2-yl, imidazo[1,2-a]pyridin-7-yl, or benzo[b]thiophen-2-yl, where said fused heteroaryl is optionally substituted with 1 to 2 substituents each independently selected from fluoro, chloro, methyl, difluoromethyl, trifluoromethyl, cyclopropyl, or amino; 
 or a pharmaceutically acceptable salt thereof. 
 
     
     
       7. The compound of  claim 2  wherein R 53  is phenyl, 4-chloro-3-fluoro-phenyl, m-tolyl, 3-methoxy-phenyl, 3-chloro-4-fluoro-phenyl, 4-fluoro-3-methyl-phenyl, 3-trifluoromethyl-phenyl, 3-chloro-phenyl, 4-fluoro-3-trifluoromethyl-phenyl, 3-difluoromethyl-4-fluoro-phenyl, 3-cyano-4-fluorophenyl, 3-cyanophenyl, 3-chloro-4-cyanophenyl, 3,4-difluoro-phenyl, 4-trifluoromethyl-phenyl;
 or a pharmaceutically acceptable salt thereof. 
 
     
     
       8. The compound of  claim 2  wherein R 53  is naphthalen-2-yl, benzo[b]thiophen-5-yl, 3-methyl-benzo[d]isoxazol-5-yl, 1H-indazol-5-yl, 1-methyl-1H-indazol-5-yl, 3-amino-1H-indazol-5-yl, 1H-indazol-6-yl, 3-amino-1H-indazol-6-yl, 3-methyl-1H-indazol-6-yl, 3-trifluoromethyl-1H-indazol-6-yl, benzothiazol-6-yl, 1,2-dihydro-3-oxo-indazol-6-yl, indan-5-yl, 1H-benzotriazol-5-yl, 3-methyl-benzofuran-5-yl, 2,3-dihydro-benzo[1,4]dioxin-6-yl, 2,3-dihydro-benzofuran-5-yl, or 2,2-difluoro-benzo[1,3]dioxol-5-yl;
 or a pharmaceutically acceptable salt thereof. 
 
     
     
       9. The compound of  claim 8  wherein R 53  is benzothiazol-6-yl, 3-methyl-benzofuran-5-yl, 1H-indazol-6-yl, 3-methyl-1H-indazol-6-yl, or 3-trifluoromethyl-1H-indazol-6-yl;
 or a pharmaceutically acceptable salt thereof. 
 
     
     
       10. The compound of  claim 2  wherein R 53  is 5-methyl-thiophen-2-yl, 5-chloro-thiophen-2-yl, 5-trifluoromethyl-thiophen-2-yl, 5-difluoromethyl-thiophen-3-yl, 5-methyl-thiophen-3-yl, 2-methyl-pyridin-4-yl, 2-trifluoromethyl-pyridin-4-yl, 2-chloro-pyridin-4-yl, or 2-methoxy-pyridin-4-yl;
 or a pharmaceutically acceptable salt thereof. 
 
     
     
       11. The compound of  claim 2  wherein R 53  is 4-chloro-thieno[3,2-c]pyridin-2-yl, 4-chloro-thieno[3,2-c]pyridin-3-yl, thieno[3,2-c]pyridin-2-yl, 3-chloro-imidazo[1,2-a]pyridin-7-yl, benzo[b]thiophen-2-yl, or 4-methylthieno[3,2-c]pyridin-2-yl;
 or a pharmaceutically acceptable salt thereof. 
 
     
     
       12. A compound selected from the group consisting of
 1-Benzothiazol-6-yl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(2-Chloro-pyridin-4-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(4-Chloro-thieno[3,2-c]pyridin-2-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(1H-Indazol-6-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(3-Methyl-1H-indazol-6-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; and 
 1-Benzothiazol-6-yl-4-methyl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; Or a pharmaceutically acceptable salt thereof. 
 
     
     
       13. A compound selected from the group consisting of
 1-Naphthalen-2-yl-3-pyridin-3-yl-imidazolidin-2-one; 
 1-Benzo [b]thiophen-5-yl-3-pyridin-3-yl-imidazolidin-2-one; 
 1-(4-Methyl-pyridin-3-yl)-3-naphthalen-2-yl-imidazolidin-2-one; 
 1-(4-Methyl-pyridin-3-yl)-3-(5-methyl-thiophen-2-yl)-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-Benzo[b]thiophen-2-yl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-Benzo[b]thiophen-5-yl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(1H-Indazol-5-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(3-Methyl-benzofuran-5-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(5-Chloro-thiophen-2-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(3,4-Difluoro-phenyl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(3-Chloro-4-fluoro-phenyl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(2,3-Dihydro-benzofuran-5-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(4-Chloro-3-fluoro-phenyl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(4-Methyl-pyridin-3-yl)-3-m-tolyl-imidazolidin-2-one; 
 1-(3-Methoxy-phenyl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(2-Chloro-pyridin-4-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(4-Fluoro-3-methyl-phenyl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(2,2-Difluoro-benzo[1,3]dioxol-5-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(4-Methyl-pyridin-3-yl)-3-phenyl-imidazolidin-2-one; 
 1-(4-Methyl-pyridin-3-yl)-3-(3-trifluoromethyl-phenyl)-imidazolidin-2-one; 
 1-(2-Methoxy-pyridin-4-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(5-Difluoromethyl-thiophen-3-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(3-Chloro-phenyl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(4-Fluoro-3-trifluoromethyl-phenyl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(3-Difluoromethyl-4-fluoro-phenyl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(4-Methyl-pyridin-3-yl)-3-(5-methyl-thiophen-3-yl)-imidazolidin-2-one; 
 1-(4-Chloro-thieno[3,2-c]pyridin-2-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(4-Chloro-thieno[3,2-c]pyridin-3-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(4-Methyl-pyridin-3-yl)-3-(2-methyl-pyridin-4-yl)-imidazolidin-2-one; 
 1-(3-Methyl-benzo[d]isoxazol-5-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(3-Methyl-1H-indazol-6-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 2-Fluoro-5-[3-(4-methyl-pyridin-3-yl)-2-oxo-imidazolidin-1-yl]-benzonitrile; 
 3-[3-(4-Methyl-pyridin-3-yl)-2-oxo-imidazolidin-1-yl]-benzonitrile; 
 2-Chloro-4-[3-(4-methyl-pyridin-3-yl)-2-oxo-imidazolidin-1-yl]-benzonitrile; 
 1-(1-Methyl-1H-indazol-5-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(3-Amino-1H-indazol-5-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(4-Methyl-pyridin-3-yl)-3-thieno[3,2-c]pyridin-2-yl-imidazolidin-2-one; 
 1-(1H-Indazol-6-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(3-Amino-1H-indazol-6-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-3-(4-methoxy-pyridin-3-yl)-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-3-(4-difluoromethyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-3-(4-hydroxymethyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-3-(4-trifluoromethyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-Indan-5-yl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(1H-Benzotriazol-5-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(3-Chloro-imidazo[1,2-a]pyridin-7-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(4-Methyl-pyridin-3-yl)-3-(2-trifluoromethyl-pyridin-4-yl)-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-3-(4-dimethoxymethyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-3-(5-chloro-4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(4-Methylpyridin-3-yl)-3-(5-(trifluoromethyl)thiophen-2-yl)imidazolidin-2-one; 
 1-(4-Methylpyridin-3-yl)-3-(4-methylthieno[3,2-c]pyridin-2-yl)imidazolidin-2-one; 
 1-(Benzo[d]thiazol-6-yl)-3-(4-(1-hydroxyethyl)pyridin-3-yl)imidazolidin-2-one; 
 1-(Benzo[d]thiazol-6-yl)-3-(4-ethylpyridin-3-yl)imidazolidin-2-one; 
 1-(4-Methylpyridin-3-yl)-3-(3-(trifluoromethyl)-1H-indazol-6-yl)imidazolidin-2-one; 
 1-Benzothiazol-6-yl-4-methyl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-3-pyridin-3-yl-4-trifluoromethyl-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-4-methyl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 3-Benzothiazol-6-yl-1-pyridin-3-yl-4-trifluoromethyl-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-3-(4-methyl-pyridin-3-yl)-4-trifluoromethyl-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-4,5-dimethyl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-3-(4-pyrrolidin-1-ylmethyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-3-(4-morpholin-4-ylmethyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-3-(4-cyclopropylaminomethyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-3-(6-fluoro-4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-3-[4-(2-morpholin-4-yl-ethoxy)-pyridin-3-yl]-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-3-[4-(1-methyl-pyrrolidin-2-yl-methoxy)-pyridin-3-yl]-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-3-{4-[(5-methyl-1H-pyrazol-3-ylamino)-methyl]-pyridin-3-yl}-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-3-[4-(1-methyl-piperidin-4-yl-methoxy)-pyridin-3-yl]-imidazolidin-2-one; 
 3-(3-Benzothiazol-6-yl-2-oxo-imidazolidin-1-yl)-isonicotinamide; 
 1-Benzothiazol-6-yl-3-(4-methyl-5-trifluoromethyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-Isothiazol-4-yl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(4-Methyl-pyridin-3-yl)-3-(5-trifluoromethyl-thiophen-2-yl)-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-3-[4-(1-hydroxy-1-methyl-ethyl)-pyridin-3-yl]-imidazolidin-2-one; 
 1-(4-Methyl-pyridin-3-yl)-3-(4-methyl-thieno[3,2-c]pyridin-2-yl)-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-3-[4-(1-hydroxy-ethyl)-pyridin-3-yl]-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-3-(4-ethyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(4-Methyl-pyridin-3-yl)-3-(3-trifluoromethyl-1H-indazol-6-yl)-imidazolidin-2-one; 
 1-(3-Cyclopropyl-1H-indazol-6-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-(4-Methyl-pyridin-3-yl)-3-quinolin-7-yl-imidazolidin-2-one; 
 3-Benzothiazol-6-yl-4,4-dimethyl-1-(4-methyl-pyridin-3-yl)-imidazolidin-2-one: 
 1-Benzothiazol-6-yl-4,4-dimethyl-3-pyridin-3-yl-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-4,4-dimethyl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 3-Benzothiazol-6-yl-4-methyl-1-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-4-methyl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-4,5-dimethyl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-3-(4-pyrrolidin-1-ylmethyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-3-(4-morpholin-4-ylmethyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-3-(4-cyclopropylaminomethyl-pyridin-3-yl)-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-3-{4-[(5-methyl-1H-pyrazol-3-ylamino)-methyl]-pyridin-3-yl}-imidazolidin-2-one; 
 1-Benzothiazol-6-yl-4,4-dimethyl-3-pyridin-3-yl-imidazolidin-2-one; and 
 3-Benzothiazol-6-yl-4-methyl-1-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; 
 
       or a pharmaceutically acceptable salt thereof. 
     
     
       14. A pharmaceutical composition comprising a compound of  claim 2  or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient. 
     
     
       15. The pharmaceutical composition of  claim 14  further comprising at least one additional pharmaceutical agent wherein said at least one additional pharmaceutical agent is an anticancer agent, chemotherapy agent, or antiproliferative compound. 
     
     
       16. A compound which is 1-(2-Chloro-pyridin-4-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one having the structure: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
       17. A pharmaceutical composition comprising a compound according to claim 16, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.  
     
     
       18. The pharmaceutical composition of claim 17 further comprising at least one additional pharmaceutical agent wherein said at least one additional pharmaceutical agent is an anticancer agent, chemotherapy agent, or antiproliferative compound.  
     
     
       19. A compound which is 1-(2-Chloro-pyridin-4-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one having the structure:  
       
         
           
           
               
               
           
         
       
     
     
       20. A pharmaceutical composition comprising a compound according to claim 19 and a pharmaceutically acceptable carrier or excipient.  
     
     
       21. The pharmaceutical composition of claim 20 further comprising at least one additional pharmaceutical agent wherein said at least one additional pharmaceutical agent is an anticancer agent, chemotherapy agent, or antiproliferative compound.